Trials / Completed
CompletedNCT03359213
A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)
Phase II Study of JR-141 in Patients With Mucopolysaccharidosis II
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- JCR Pharmaceuticals Co., Ltd. · Industry
- Sex
- Male
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
A Phase II open-label, randomized, parallel group, 2 sites (Brazil), designed to evaluate the safety and efficacy of 3 doses of study drug for the treatment of the MPS II.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JR-141 | IV infusion (lyophilized powder), 1.0 mg/kg/week |
| DRUG | JR-141 | IV infusion (lyophilized powder), 2.0 mg/kg/week |
| DRUG | JR-141 | IV infusion (lyophilized powder), 4.0 mg/kg/week |
Timeline
- Start date
- 2018-07-26
- Primary completion
- 2019-10-04
- Completion
- 2019-10-04
- First posted
- 2017-12-02
- Last updated
- 2025-07-24
Locations
2 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03359213. Inclusion in this directory is not an endorsement.